CLINICAL NEWS
Dexamethasone Versus Prednisone in Pediatric
Patients with ALL
progression-free survival at 18 months
was also higher (86% and 88% vs. 55%
and 63%, respectively; p=0.02 and p=0.09,
respectively).
Ponatinib was also effective in CPCML patients without the T315I mutation, but who had inferior responses to
treatment with second-generation TKIs
(nilotinib and/or dasatinib) following
imatinib